Acumen Pharmaceuticals (ABOS) Operating Income (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Operating Income of -$21.1 million in Q1 2026, up 16.07% quarter-over-quarter from -$25.2 million in Q4 2025, and up 30.36% year-over-year from -$16.2 million in Q1 2025.
Acumen Pharmaceuticals' Operating Income history runs 7 years deep, the most recent figure standing at -$21.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 30.36% year-over-year to -$21.1 million; the TTM figure through Mar 2026 stood at -$114.6 million (up 9.48% YoY), while the FY2025 annual figure was -$123.8 million, down 8.61% from the prior year.
- Operating Income came in at -$21.1 million for Q1 2026 at Acumen Pharmaceuticals, up from -$25.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$9.2 million in Q1 2022 to a low of -$41.8 million in Q2 2025.
- A 5-year average of -$21.5 million and a median of -$18.5 million in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income tumbled 202.56% in 2022 and jumped 36.36% in 2025, its largest moves.
- Acumen Pharmaceuticals' Operating Income stood at -$14.2 million in 2022, then decreased by 29.74% to -$18.5 million in 2023, then sank by 114.2% to -$39.6 million in 2024, then surged by 36.36% to -$25.2 million in 2025, then advanced by 16.07% to -$21.1 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$21.1 million, -$25.2 million, and -$26.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.15 Mn |
| Dec 31, 2025 | -25.20 Mn |
| Sep 30, 2025 | -26.51 Mn |
| Jun 30, 2025 | -41.75 Mn |
| Mar 31, 2025 | -30.37 Mn |
| Dec 31, 2024 | -39.60 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Jun 30, 2024 | -24.38 Mn |
| Mar 31, 2024 | -17.77 Mn |
| Dec 31, 2023 | -18.49 Mn |
| Sep 30, 2023 | -16.04 Mn |
| Jun 30, 2023 | -13.48 Mn |
| Mar 31, 2023 | -13.14 Mn |
| Dec 31, 2022 | -14.25 Mn |
| Sep 30, 2022 | -11.37 Mn |
| Jun 30, 2022 | -10.41 Mn |
| Mar 31, 2022 | -9.21 Mn |
| Dec 31, 2021 | -8.42 Mn |
| Sep 30, 2021 | -3.94 Mn |
| Jun 30, 2021 | -3.44 Mn |
| Mar 31, 2021 | -3.79 Mn |
| Dec 31, 2020 | -1.34 Mn |
| Sep 30, 2020 | -2.49 Mn |
| Jun 30, 2020 | -2.04 Mn |